Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
14. Dezember 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...
Protalix BioTherapeutics Announces Investor Call
01. Dezember 2016 17:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Company will hold an investor conference call on December 2, 2016...
Protalix BioTherapeutics Announces Private Note Exchanges and Private Placement of Secured Convertible Notes due 2021
01. Dezember 2016 16:44 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today the entry into a definitive exchange agreement relating to...
Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
30. November 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enrolled in its phase II clinical trial...
Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older
22. November 2016 09:24 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health Surveillance Agency (ANVISA,...
Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results
09. November 2016 08:00 ET
|
Protalix BioTherapeutics, Inc.
Patient Enrollment Ongoing for Phase III Fabry Clinical Trial with approximately 10 Patients Currently in Evaluation and Screening Stages Enrollment for the Phase II Cystic Fibrosis Clinical Trial...
Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease
25. Oktober 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been dosed in its global phase III clinical...
Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism
07. September 2016 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today an oral presentation highlighting the results of the phase I/II...
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
10. August 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additional positive data from its phase I/II clinical trial of...
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
08. August 2016 16:30 ET
|
Protalix BioTherapeutics, Inc.
Patient Screening Underway for Fabry Phase III Clinical Trial Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End CARMIEL, Israel, Aug. 08, 2016 (GLOBE NEWSWIRE) --...